The discovery that GNAS copy number gain can significantly increase tumor cell proliferation suggests that inhibitor therapy targeting CDK6 (cyclin-dependent kinase 6) might prove effective for PIT1 (pituitary-specific positive transcription factor 1) lineage patients with GNAS copy number amplification [117]. This evidence concerns the gene CDK6 and neoplasm.